Although huge strides have been made with antiretroviral therapy (ART) and prevention since HIV was first reported 42 years ago, there is still not an effective preventive vaccine or a scalable cure for those living with HIV. But broadly neutralizing antibodies (bNAbs) look to be a further step down the pathway to a cure, speakers said during the International AIDS Society meeting held July 23 to 26 in Brisbane, Australia.
Suzhou Ark Biopharmaceutical Co. Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Sandfly bites transmit the intracellular protozoan Leishmania to cause leishmaniasis that exhibits with clinical presentations ranging from a cutaneous ulcer to treatment-resistant lethal systemic disease (visceral leishmaniasis; VL). VL reportedly kills 20,000 to 30,000 every year according to the World Health Organization, where current medications are limited by side effects and evolving antibiotic resistance. Accordingly, there is a great need to develop alternatives.
Researchers from Collaborations Pharmaceuticals Inc. recently reported the discovery and preclinical evaluation of a novel pleconaril-based molecule, 11526092, being develop as an antiviral agent against enteroviruses.
In a recent publication, researchers from Institute of Medicinal Biotechnology and affiliated organizations described a novel group of antitubercular agents with an improved safety profile.
The HIV journey is a roller coaster of highs and lows for the patients living with HIV and their families and loved ones but also for the community of researchers and clinicians who pour their hearts and souls into the work they do, said speakers at the International AIDS Society (IAS) 2023 conference in Brisbane, Australia.
Shanghai Curegene Pharmaceutical Co. Ltd. has synthesized macrocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Giardia lamblia is a protozoan pathogen that colonizes the gastrointestinal tract and results in giardiasis. Recently, researchers from the University of California San Diego aimed to identify potent proteasome inhibitors that selectively target G. lamblia, as potential antigiardiasis therapeutics with low toxicity.
The HIV journey is a roller coaster of highs and lows for the patients living with HIV and their families and loved ones but also for the community of researchers and clinicians who pour their hearts and souls into the work they do, said speakers at the International AIDS Society (IAS) 2023 conference in Brisbane, Australia.
Bacteria cells are masters of adaptation and evolution, and by better understanding how they adapt and evolve, researchers hope to develop better drugs to fight microbial resistance, which is increasingly becoming a global public health threat. Researchers from the antimicrobial resistance interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART) sought to understand the mechanisms bacteria use to adapt against stressors, and they discovered a new stress signaling system that sheds light on a new mechanism of antimicrobial resistance.
RSS
